The approval of the vaccine, called mFLUSIVA, which is manufactured by Moderna, follows a series of blows to mRNA research ...
FLUSIVA becomes Moderna's fifth approved product globally and fourth FDA-approved productCompany expects supply to be ...
Phase 1 trial will evaluate safety and immune response for a strain of Ebola virus disease with no licensed vaccines ...
The Food and Drug Administration has approved a new kind of flu vaccine for older people, the first made with the same mRNA ...
Moderna (MRNA) valuation in focus: weak Q2, cash outlook, FDA win for mFLUSIVA, pipeline risks and sales hurdles.
The decision caps a seven-month process that included a rare refusal to consider the shot.
The FDA’s approval is welcome news, and will hopefully open the door to much faster production of an effective vaccine to ...
The FDA has approved Moderna’s influenza vaccine, the first licensed flu shot made using messenger RNA technology.
The mFlusiva vaccine will soon be available for adults aged 50 and over.
Moderna received FDA approval for its new mRNA-based flu shot for older adults after months of regulatory questioning.
The Food and Drug Administration has approved a new flu vaccine made with the same mRNA technology that was used for the COVID-19 shots.
The Food and Drug Administration on Wednesday approved the U.S.’s first flu shot that uses mRNA technology: mFlusiva, from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results